Skip to main content
Smart Investors Daily
VE

NASDAQ · VERA

Vera Therapeutics, Inc.

Healthcare · Biotechnology

$30.42

Down-$0.57 (-1.84%)

Updated Oct 5, 2026, 6:21 AM

SID Score

4.0/10

Composite research score

Smart Money

62/100

Neutral

Market cap
2.94B
P/E ratio
-13.44
Dividend yield
0.00%
52-week range
$28.86 – $47.00
Volume
1.61M
Avg. volume
1.59M

Price performance · VERA

VERA price history

1M range · 0 trading sessions · Daily adjusted prices

VERA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest VERA news

The latest Smart Investors Daily articles mentioning VERA.

VERA research

Overview

Company profile and research snapshot.

Company profile

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$73.25
Implied upside
—
Analysts
—
VERA recent ratings
DateFirmRatingTarget
Sep 8, 2026JP MorganOverweight—
Aug 17, 2026WedbushNeutral—
Aug 12, 2026HC Wainwright & Co.Buy—
Aug 11, 2026WedbushNeutral—
Jul 8, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be Brewing

Should you short stocks right now? That’s a good question, and it’s one with no clear answer. There’s still a bullish feeling in the air, but volatility is rising, and there’s no guarantee the bulls will keep running. In a market like this, it can be tempting to bet against stocks. Shorting a stock can be a fast track to profits, but it’s also a fast track to risk. A short seller borrows shares and sells them, hoping to buy them back later at a lower price. If the stock rises instead, the short

Yahoo · Sep 17, 2026

Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints

Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. The confirmation of TRUTAKNA's Phase III success sits against a wider backdrop of...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.